| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRNa4 |
| Uniprot No | P43681 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-627aa |
| 氨基酸序列 | MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKRPSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI |
| 预测分子量 | 69,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于CHRNA4重组蛋白研究的参考文献概览(注：文献信息为模拟生成，实际引用请核实原文)：
---
1. **文献名称**：*Expression and functional characterization of recombinant human α4β2 nicotinic acetylcholine receptors*
**作者**：Pusch M, Bertrand D
**摘要**：本研究在HEK-293细胞中表达了人源CHRNA4与CHRNB2亚基的重组蛋白，通过电生理学方法证实其形成功能性烟碱型乙酰胆碱受体(nAChR)，并验证了其对乙酰胆碱和尼古丁的剂量依赖性响应。
---
2. **文献名称**：*Structural insights into the α4 subunit of nicotinic receptors by cryo-EM*
**作者**：Kukhtina V, et al.
**摘要**：利用冷冻电镜技术解析了重组CHRNA4/β2受体蛋白的3D结构，揭示了亚基间相互作用的关键氨基酸残基及配体结合位点的构象变化机制。
---
3. **文献名称**：*Epilepsy-associated mutations in CHRNA4 alter receptor desensitization kinetics*
**作者**：McLaughlin JT, et al.
**摘要**：通过表达携带家族性癫痫相关突变(如S248F)的CHRNA4重组蛋白，发现突变显著延长受体脱敏时间，提示离子通道功能异常与疾病表型的关联。
---
**备注**：以上文献标题与内容为领域典型研究方向示例，实际研究需通过PubMed、Google Scholar等平台以“CHRNA4 recombinant protein”“nAChR α4 subunit”等关键词检索近年文献。
The CHRNA4 gene encodes the α4 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), ligand-gated ion channels critical for synaptic transmission in the central and peripheral nervous systems. These receptors are pentameric complexes, typically combining α (α2-α7) and β (β2-β4) subunits. The α4β2 combination is the most prevalent nAChR subtype in the brain, playing roles in cognition, reward pathways, and neurotransmitter release. CHRNA4 mutations are linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and associated with neuropsychiatric disorders like ADHD and addiction.
Recombinant CHRNA4 protein is produced via genetic engineering, often in mammalian systems (e.g., HEK293 cells) or bacterial expression platforms. The purified protein retains functional receptor properties, enabling structural and functional studies. Researchers use it to investigate receptor assembly, ligand binding (e.g., acetylcholine, nicotine), ion channel kinetics, and the impact of disease-associated mutations. For example, certain ADNFLE-linked CHRNA4 variants alter receptor desensitization, providing insights into hyperexcitability mechanisms.
Pharmaceutically, recombinant CHRNA4 facilitates drug discovery targeting nAChRs. It aids in screening compounds for epilepsy, smoking cessation therapies, or cognitive enhancers. Additionally, it serves as an antigen for antibody development in diagnostic or research tools. Studies combining CHRNA4 with β2 subunits help dissect subtype-specific pharmacology, critical for designing selective drugs with minimized side effects. Overall, recombinant CHRNA4 is a vital tool for advancing neuroscience research and therapeutic innovation.
×
